

AN 1998:112682 CAPLUS
DN 128:221671
TI Improved cancer treatment with temozolomide
IN Radenburg, Pascal; Dougan, Margaret H.
PA Schering Corp., USA

SO Jpn. Kokai Tokkyo Koho, 17 pp.
CODEN: JKXXAF

DT Patent

LA Japanese

IC ICM A61K031-415

ICS C07D487-04

CC 63-6 (Pharmaceuticals)

Section cross-reference(s): 1

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 10045589	A2	19980217	JP 1996-232394	19960902
	CA 2184545	AA	19980201	CA 1996-2184545	19960830
PRAI	US 1996-690707		19960731		

AB A method for treating cancer in a patient in need of such treatment comprises administering temozolomide in an amt. sufficient to achieve a clin. response, wherein the temozolomide is administered more than once per day. Preferred aspect of the invention is administration

of temozolomide twice, three times or four times per day. A capsule contained temozolomide 5, lactose 132.8, Na starch glycolate 7.5, colloidal silica 0.2, tartaric acid 1.5, and stearic acid 3 mg.

ST temozolomide capsule cancer treatment

IT Oral drug delivery systems

(bolus; improved cancer treatment with temozolomide)

IT Brain tumor inhibitors

Breast tumor inhibitors

Capsules (drug delivery systems)

Carcinoma inhibitors

Colon tumor inhibitors

Glioblastoma inhibitors

Glioma inhibitors

Leukemia inhibitors

Lung tumor inhibitors

Lymphoma inhibitors

Melanoma inhibitors

Sarcoma inhibitors

(improved cancer treatment with temozolomide)

IT Testicular tumors

(inhibitors; improved cancer treatment with temozolomide)

IT Skin tumors

T cell lymphoma

(mycosis fungoides, inhibitors; improved cancer treatment with temozolomide)

IT Antitumor agents

Colorectal tumors

(rectal tumor inhibitors; improved cancer treatment with temozolomide)

IT Antitumor agents

(testicular; improved cancer treatment with temozolomide)

IT 85622-93-1, Temozolomide

RL: BAC (Biological activity or effector, except adverse); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(improved cancer treatment with temozolomide)